Compound · clinical trials

Tislelizumab clinical trials

Also listed in trial records as BGB-A317, Tevimbra, Baizean, VDT482

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 251 trials in our China, USA, Spain, Germany, Australia, Italy, Japan, South Korea, Taiwan, France, Canada, UK, Brazil, Netherlands, Belgium, Poland, Turkey, Mexico, Singapore, Austria, Denmark, Israel, Czechia, Egypt, Ireland, India, Portugal, Sweden and Norway registers that name Tislelizumab as an intervention. Synced 11 Nov 2026

251Current trials

159Recruiting now

127Lead sponsors

29Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 11 Nov 2026 · Editorial standards

At a glance

Tislelizumab is named as an intervention in 251 current clinical trials in our China, USA, Spain, Germany, Australia, Italy, Japan, South Korea, Taiwan, France, Canada, UK, Brazil, Netherlands, Belgium, Poland, Turkey, Mexico, Singapore, Austria, Denmark, Israel, Czechia, Egypt, Ireland, India, Portugal, Sweden and Norway registers. 159 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (18). The most-studied condition is Esophageal Squamous Cell Carcinoma. The EU clinical trials register (CTIS) separately lists 5 authorised or ongoing trials.

Where Tislelizumab is approved

All regulators →

Of the three regulators tracked here, the first to approve Tislelizumab was the EU, on 15 Sep 2023. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)

13 Mar 2024

Tevimbra

BLA761232 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

15 Sep 2023

Tevimbra

EMA product page

First centralised authorisation

CACanada (Health Canada)

18 Dec 2025

Tevimbra

Notice of Compliance 36584

First new-drug NOC

3 EU orphan designations, most recently for treatment of hepatocellular carcinoma (6 Mar 2024, withdrawn)

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

How Tislelizumab works

All drug targets →

Programmed cell death protein 1 inhibitor Inhibitor
Target: PDCD1 programmed cell death 1
✓ In ChEMBL and the Guide to Pharmacology

Other medicines acting on PDCD1

Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Cadonilimab Serplulimab Cemiplimab Dostarlimab Pucotenlimab Zimberelimab Penpulimab +8 more

Diseases it has been tested for in clinical trials, by furthest phase

B-cell chronic lymphocytic leukemiaPhase 3
Bone metastasisPhase 3
Breast cancerPhase 3
CancerPhase 3
CholangiocarcinomaPhase 3
Classic Hodgkin lymphomaPhase 3
Colorectal cancerPhase 3
Diffuse large B-cell lymphomaPhase 3
Gastric adenocarcinomaPhase 3
Gastroesophageal junction adenocarcinomaPhase 3

99 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297840, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9592, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Tislelizumab

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 3 technology appraisals of Tislelizumab. 3 are current.

Appraisal	NICE recommendation	Published	Status
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) NICE TA1072	Terminated (no company submission)	19 Jun 2025	Current
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) NICE TA1068	Terminated (no company submission)	29 May 2025	Current
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) NICE TA1058	Terminated (no company submission)	23 Apr 2025	Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Tislelizumab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 1 product on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
EU
European Union: Tevimbra
EMA product information: package leaflet and summary of product characteristics in every EU language.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting15963%
Not yet open5321%
Active, closed3614%
By invitation31%

Trials by phase

Phase 213855%
Phase 33916%
Phase 1/22610%
Phase 12510%
Phase 2/373%
Observational62%
Phase 442%
Not applicable31%
Early Phase 131%

Clinical trials of Tislelizumab

251 trials

Study	Phase	Status	Lead sponsor	Registers
Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) NCT07320105 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 4	Recruiting	Fujian Cancer Hospital	China
Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) NCT07744698 · ClinicalTrials.gov ↗ · Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 4	Recruiting	Anhui Provincial Cancer Hospital	China
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma NCT05342792 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma NCT05919030 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Renmin Hospital of Wuhan University	China
Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC NCT06177301 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Fudan University	China
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease NCT06332274 · ClinicalTrials.gov ↗ · Cancer, Lung Cancer, Colo-rectal Cancer	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. NCT06383780 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	XIANG YANQUN	China
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation NCT06416410 · ClinicalTrials.gov ↗ · Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer	Phase 3	Recruiting	Allist Pharmaceuticals, Inc	China
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer NCT06441110 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active	Phase 3	Recruiting	Fujian Medical University Union Hospital	China
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer NCT06520683 · ClinicalTrials.gov ↗ · Colorectal Cancer, Microsatellite Instability High	Phase 3	Recruiting	Sun Yat-sen University	China
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study NCT06598527 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC)	Phase 3	Recruiting	Yang Hong	China
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy NCT06745908 · NSCLC Stage IV	Phase 3	Recruiting	ImmunityBio, Inc	UK, USA, Canada
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma NCT06793917 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fujian Cancer Hospital	China
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07043400 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	BeOne Medicines	UK, USA, China, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Brazil, Mexico, Japan, South Korea
Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study NCT07132463 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Fudan University	China
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07315750 · ClinicalTrials.gov ↗ · Gastric Carcinoma	Phase 3	Recruiting	RemeGen Co., Ltd	China
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07385703 · ClinicalTrials.gov ↗ · Adenocarcinoma	Phase 3	Recruiting	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd	China, Japan
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) NCT07416474 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Recruiting	RemeGen Co., Ltd	China
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence NCT07475026 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 3	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) NCT07502300 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer NCT07802821 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd	China
A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma NCT07925021 · ClinicalTrials.gov ↗ · Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma	Phase 3	Recruiting	CSPC Megalith Biopharmaceutical Co.,Ltd	China
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC NCT04973306 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III	Phase 2/3	Recruiting	Shanghai Zhongshan Hospital	China
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer NCT05699655 · ClinicalTrials.gov ↗ · Immunotherapy Gastrict Cancer	Phase 2/3	Recruiting	Fujian Cancer Hospital	China
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer NCT06312982 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Carcinoma	Phase 2/3	Recruiting	Beijing Friendship Hospital	China
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment NCT06563245 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma, Child, Adolescent	Phase 2/3	Recruiting	Children's Cancer Group, China	China
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) NCT07554456 · Esophageal Squamous Cell Carcinoma	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer NCT07662395 · ClinicalTrials.gov ↗ · Double Blind	Phase 2/3	Recruiting	Sinocelltech Ltd	China
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors NCT03736889 · ClinicalTrials.gov ↗ · MSI-H/dMMR Solid Tumors	Phase 2	Recruiting	BeiGene	China
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation NCT04271956 · ClinicalTrials.gov ↗ · Richter Transformation	Phase 2	Recruiting	German CLL Study Group	Germany, Denmark, Austria
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC NCT04501523 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC NCT04615143 · ClinicalTrials.gov ↗ · Recurrent Hepatocellular Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma NCT04837859 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma	Phase 2	Recruiting	University of Cologne	Germany
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma NCT04954781 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Fudan University	China
Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma NCT05057845 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 2	Recruiting	Fudan University	China
Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer NCT05360277 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer，NED	Phase 2	Recruiting	Yanhong Deng	China
Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type NCT05477264 · ClinicalTrials.gov ↗ · Lymphoma	Phase 2	Recruiting	Won Seog Kim	South Korea
Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer NCT05511623 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2	Recruiting	First Affiliated Hospital of Guangxi Medical University	China
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma NCT05512351 · ClinicalTrials.gov ↗ · Oligodendroglioma	Phase 2	Recruiting	Henan Provincial People's Hospital	China
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma NCT05515315 · ClinicalTrials.gov ↗ · Immunotherapy Esophagus Cancer	Phase 2	Recruiting	Fuzhou General Hospital	China
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) NCT05536102 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence NCT05557578 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Zhejiang Cancer Hospital	China
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma NCT05687357 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal-junction Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients NCT05771181 · ClinicalTrials.gov ↗ · Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma	Phase 2	Recruiting	Fudan University	China
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC) NCT05837806 · ClinicalTrials.gov ↗ · Neoadjuvant Immunotherapy	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial NCT05862168 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma	Phase 2	Recruiting	Weijia Fang, MD	China
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients NCT05912816 · ClinicalTrials.gov ↗ · Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC	Phase 2	Recruiting	RenJi Hospital	China
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy NCT05977673 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma	Phase 2	Recruiting	Fondazione Italiana Linfomi - ETS	Italy
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11) NCT06032845 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 2	Recruiting	Fudan University	China
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma NCT06056336 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy	Phase 2	Recruiting	Guo Xufeng	China
Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC NCT06132698 · ClinicalTrials.gov ↗ · NSCLC Associated With Leptomeningeal Metastases	Phase 2	Recruiting	West China Hospital	China
Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore NCT06157996 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Nanfang Hospital, Southern Medical University	China
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T NCT06167785 · Large B-cell Lymphoma	Phase 2	Recruiting	University Health Network, Toronto	Canada
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer NCT06254521 · ClinicalTrials.gov ↗ · Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III	Phase 2	Recruiting	First Affiliated Hospital of Guangxi Medical University	China
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY NCT06354140 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC NCT06379087 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Ji Yongling	China
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) NCT06387056 · ClinicalTrials.gov ↗ · Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model NCT06420440 · HCC	Phase 2	Recruiting	Chen Xiaoping	China
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma NCT06446726 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan University	China
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer NCT06451211 · ClinicalTrials.gov ↗ · Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach	Phase 2	Recruiting	Sun Yat-sen University	China
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC NCT06536868 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Recruiting	Second Hospital of Shanxi Medical University	China
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study NCT06538896 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer, Bone Metastases	Phase 2	Recruiting	Zhejiang Cancer Hospital	China
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma NCT06646588 · Esophageal Neoplasms	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer NCT06659042 · ClinicalTrials.gov ↗ · Lung Cancer, Non-Small Cell	Phase 2	Recruiting	Shanghai Chest Hospital	China
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma NCT06664021 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Anhui Provincial Hospital	China
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL NCT06695013 · ClinicalTrials.gov ↗ · B-NHL, CART Therapy	Phase 2	Recruiting	Ruijin Hospital	China
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer NCT06709885 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma	Phase 2	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities NCT06722183 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression NCT06749860 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting NCT06749886 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma NCT06764355 · ClinicalTrials.gov ↗ · ESCC, Total Neoadjuvant Treatment, Pathological Complete Response	Phase 2	Recruiting	National Taiwan University Hospital	Taiwan
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" NCT06829355 · ClinicalTrials.gov ↗ · MCRC	Phase 2	Recruiting	Beijing Friendship Hospital	China
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) NCT06849986 · ClinicalTrials.gov ↗ · Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma	Phase 2	Recruiting	Fudan University	China
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases NCT06856837 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany, Austria
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) NCT06860477 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocellular Carcinoma	Phase 2	Recruiting	Fudan University	China
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer NCT06877299 · ClinicalTrials.gov ↗ · Lung Cancer, Non-small Cell Lung Cancer	Phase 2	Recruiting	Sichuan University	China
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer NCT06881537 · ClinicalTrials.gov ↗ · Locally Recurrent Colorectal Cancer	Phase 2	Recruiting	Shanghai Changzheng Hospital	China
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer. NCT06940388 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC)	Phase 2	Recruiting	brenner baruch	Germany, Israel
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC NCT06978829 · ClinicalTrials.gov ↗ · LA HNSCC	Phase 2	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
A Study of SKB518 in Patients With Lung Cancer NCT07019675 · ClinicalTrials.gov ↗ · Lung Carcinoma	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma NCT07030140 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer	Phase 2	Recruiting	Jinbo Yue	China
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma NCT07039162 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer	Phase 2	Recruiting	Ming-Yu Lien	China, Taiwan
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab NCT07047586 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC NCT07050056 · ClinicalTrials.gov ↗ · Resectable NSCLC	Phase 2	Recruiting	Northern Jiangsu People's Hospital	China
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL NCT07058103 · ClinicalTrials.gov ↗ · Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory	Phase 2	Recruiting	The Affiliated Hospital of Xuzhou Medical University	China
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer NCT07086456 · Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy	Phase 2	Recruiting	Sun Yat-sen University	China
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma NCT07099547 · ClinicalTrials.gov ↗ · Biliary Tract Carcinoma	Phase 2	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement NCT07104604 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Recruiting	Affiliated Cancer Hospital of Shantou University Medical College	China
Perioperative Immunotherapy for Resectable Limited-Stage SCLC NCT07109401 · ClinicalTrials.gov ↗ · Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer	Phase 2	Recruiting	Fudan University	China
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC NCT07126119 · ClinicalTrials.gov ↗ · Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo) NCT07147426 · ClinicalTrials.gov ↗ · Head &Amp; Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC NCT07157969 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL NCT07168317 · ClinicalTrials.gov ↗ · New Diagnosed Angioimmunoblastic T-Cell Lymphoma	Phase 2	Recruiting	The Affiliated Hospital of Xuzhou Medical University	China
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer NCT07233252 · ClinicalTrials.gov ↗ · Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC) NCT07264647 · ClinicalTrials.gov ↗ · Stage III NSCLC	Phase 2	Recruiting	Fondazione Ricerca Traslazionale	Italy
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas NCT07290985 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	American Association for Cancer Research	Canada
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC NCT07296705 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Cancer (MIBC)	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma NCT07328009 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy NCT07330037 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] NCT07331155 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC NCT07331428 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Local Recurrence	Phase 2	Recruiting	Fujian Cancer Hospital	China
Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal NCT07370337 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of External Auditory Canal, Locally Advanced Tumor	Phase 2	Recruiting	Eye & ENT Hospital of Fudan University	China
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] NCT07390383 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma NCT07413354 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Tongji Hospital	China
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma NCT07418190 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer NCT07425795 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Phase 2	Recruiting	Chongqing University Cancer Hospital	China
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy NCT07463248 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Wang Xin	China
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer NCT07469306 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Recruiting	Fujian Cancer Hospital	China
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure NCT07528274 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States NCT07554521 · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	BeOne Medicines	USA
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes NCT07557914 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma, Diabetes	Phase 2	Recruiting	Haibo Shao	China
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma NCT07569068 · ClinicalTrials.gov ↗ · Gastric or Esophagogastric Junction Adenocarcinoma	Phase 2	Recruiting	Ruijin Hospital	China
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07601737 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer	Phase 2	Recruiting	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC NCT07609121 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)	Phase 2	Recruiting	Sun Yat-sen University	China
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors NCT07669415 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 2	Recruiting	LaNova Medicines Limited	China
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma NCT07700667 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC NCT07733180 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	BeOne Medicines	Japan
Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer NCT07811752 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Shanghai Chest Hospital	China
A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC NCT07815223 · ClinicalTrials.gov ↗ · SCLC, Limited Stage	Phase 2	Recruiting	Yantai Yuhuangding Hospital	China
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer NCT07888309 · ClinicalTrials.gov ↗ · Rectal Neoplasms, Rectal Cancer, Adenocarcinoma	Phase 2	Recruiting	Ruijin Hospital	China
Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line Immunotherapy NCT07925866 · ClinicalTrials.gov ↗ · Patients With Locally Advanced or Metastatic NSCLC Who Have Failed First-line Immunotherapy	Phase 2	Recruiting	Anhui Provincial Hospital	China
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab NCT05319639 · ClinicalTrials.gov ↗ · Gastric Cancer Stage IV	Phase 1/2	Recruiting	Fujian Cancer Hospital	China
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) NCT05431270 · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Phanes Therapeutics	USA
Genotype-guided Treatment in Newly Diagnosed PTCL NCT05675813 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma	Phase 1/2	Recruiting	Ruijin Hospital	China
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors NCT05699811 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors	Phase 1/2	Recruiting	Chinese PLA General Hospital	China
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer NCT05886439 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 1/2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
IN10018 Combination Therapy in Treatment-naïve ES-SCLC NCT06030258 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	InxMed (Shanghai) Co., Ltd	China
Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma NCT06364956 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 1/2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors NCT06427941 · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer	Phase 1/2	Recruiting	BeOne Medicines	USA, China, France, Italy, Brazil, Japan, South Korea, Egypt
Clinical Studies for the Treatment of Advanced Solid Tumors NCT06825494 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd	China
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC NCT07244705 · ClinicalTrials.gov ↗ · Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC)	Phase 1/2	Recruiting	Anbogen Therapeutics, Inc	Taiwan, Australia
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768 · Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell Lymphoma	Phase 1/2	Recruiting	Rong Tao	China
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy NCT07561060 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 1/2	Recruiting	Fudan University	China
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. NCT05547321 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Oncomatryx Biopharma S.L	USA, Spain, Israel
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors NCT05981703 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Solid Tumor	Phase 1	Recruiting	BeOne Medicines	USA, China, Australia
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma NCT05984342 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 1	Recruiting	Affiliated Cancer Hospital of Shantou University Medical College	China
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors NCT06233942 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	BeOne Medicines	USA, China, Brazil, Japan, Australia
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors NCT06349837 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Sichuan University	China
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors NCT06541639 · ClinicalTrials.gov ↗ · Advanced or Recurrent Solid Tumors	Phase 1	Recruiting	Peking University	China
A Study of BG-C477 in Participants With Advanced Solid Tumors NCT06596473 · Advanced Solid Tumors	Phase 1	Recruiting	BeOne Medicines	USA, China, Japan, South Korea, Australia, Egypt
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis NCT06848465 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastasis, LDRT	Phase 1	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC NCT06868732 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer	Phase 1	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer NCT06916494 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Cancer	Phase 1	Recruiting	First Affiliated Hospital of Chongqing Medical University	China
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC NCT06969612 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 1	Recruiting	Peking University Cancer Hospital & Institute	China
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma NCT07059299 · ClinicalTrials.gov ↗ · Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma	Phase 1	Recruiting	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients NCT07119996 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer	Phase 1	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) NCT07317609 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 1	Recruiting	Shanghai Zhongshan Hospital	China
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma NCT07377045 · Pancreatic Adenocarcinoma Metastatic	Phase 1	Recruiting	Oncomatryx Biopharma S.L	USA, Spain, Israel
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors NCT07414836 · Advanced Solid Tumor	Phase 1	Recruiting	BeOne Medicines	USA, China, Spain, Australia
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC NCT07565740 · ClinicalTrials.gov ↗ · HPV-positive Oropharyngeal Squamous Cell Carcinoma	Phase 1	Recruiting	West China Hospital	China
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations NCT07746141 · ClinicalTrials.gov ↗ · RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor	Phase 1	Recruiting	BeOne Medicines	Australia
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma NCT06323382 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab	Observational	Recruiting	Sun Yat-sen University	China
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma NCT06333561 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor	Observational	Recruiting	Sun Yat-sen University	China
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer NCT06760858 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Cancer	Observational	Recruiting	Southwest Hospital, China	China
Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC NCT07549100 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal Squamous Cell Carcinoma	Observational	Recruiting	Shandong Provincial Hospital	China
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) NCT07652736 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer	Observational	Recruiting	BeOne Medicines	Spain
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer NCT07068542 · ClinicalTrials.gov ↗ · Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma	Not applicable	Recruiting	Zhejiang Provincial People's Hospital	China
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma NCT07243691 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Recruiting	Sir Run Run Shaw Hospital	China
Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei NCT07341360 · Pseudomyxoma Peritonei	Early Phase 1	Recruiting	Oslo University Hospital	Norway
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction NCT06951841 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 4	Not yet open	China Medical University, China	China
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion NCT07790419 · ClinicalTrials.gov ↗ · Liver Cancer	Phase 4	Not yet open	Zhai Wenlong	China
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer NCT05990127 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic NSCLC	Phase 3	Not yet open	Akeso	China
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer NCT06704620 · ClinicalTrials.gov ↗ · Advanced and Metastatic NSCLC	Phase 3	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT06944496 · ClinicalTrials.gov ↗ · Gastric Carcinoma	Phase 3	Not yet open	RemeGen Co., Ltd	China
Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer NCT07068516 · ClinicalTrials.gov ↗ · Gastric Cancer Stage	Phase 3	Not yet open	Xiangdong Cheng	China
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer NCT07132008 · ClinicalTrials.gov ↗ · Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors	Phase 3	Not yet open	First Affiliated Hospital of Guangxi Medical University	China
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer NCT07383116 · ClinicalTrials.gov ↗ · Non Squamous Non-small Cell Lung Cancer	Phase 3	Not yet open	Shanghai Huaota Biopharmaceutical Co., Ltd	China
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma NCT07691515 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 3	Not yet open	Zhejiang Cancer Hospital	China
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden NCT07715396 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Metastatic	Phase 3	Not yet open	AIO-Studien-gGmbH	Germany
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma NCT07763171 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 3	Not yet open	Gruppo Oncologico del Nord-Ovest	Germany, Spain, Italy
Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations NCT07829549 · ClinicalTrials.gov ↗ · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations	Phase 3	Not yet open	RemeGen Co., Ltd	China
A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation NCT07833202 · ClinicalTrials.gov ↗ · NSCLC	Phase 3	Not yet open	Shanghai Jeyou Pharmaceutical Co., Ltd	China
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer NCT07896005 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) NCT07739186 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 2/3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer NCT04443543 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Not yet open	Fudan University	China
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma NCT05502991 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2	Not yet open	Henan Provincial People's Hospital	China
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma NCT05518994 · ClinicalTrials.gov ↗ · Astrocytoma of Brain	Phase 2	Not yet open	Henan Provincial People's Hospital	China
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma NCT05540275 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma	Phase 2	Not yet open	Henan Provincial People's Hospital	China
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations NCT06118658 · ClinicalTrials.gov ↗ · Gastric, Colorectal Adenocarcinoma	Phase 2	Not yet open	China Medical University, China	China
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. NCT06374901 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Not yet open	Xiangdong Cheng	China
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC NCT06475755 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Anti Angiogenesis	Phase 2	Not yet open	Tang-Du Hospital	China
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer NCT06554028 · ClinicalTrials.gov ↗ · Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms	Phase 2	Not yet open	Henan Cancer Hospital	China
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. NCT06630871 · ClinicalTrials.gov ↗ · NMIBC	Phase 2	Not yet open	Fujian Medical University Union Hospital	China
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia NCT06793228 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 2	Not yet open	Henan Cancer Hospital	China
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma NCT06903273 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Biliary Tract Cancer (BTC)	Phase 2	Not yet open	National Cheng-Kung University Hospital	Taiwan
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC NCT06965829 · ClinicalTrials.gov ↗ · Esophageal Cancer Stage III	Phase 2	Not yet open	Shanghai Chest Hospital	China
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC NCT06977828 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer NCT07346807 · ClinicalTrials.gov ↗ · Tongue Squamous Cell Carcinoma	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma NCT07388758 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 2	Not yet open	Sun Yat-sen University	China
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 NCT07531979 · ClinicalTrials.gov ↗ · ESCC, Tislelizumab, Chemotherapy	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC NCT07561983 · ClinicalTrials.gov ↗ · Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy	Phase 2	Not yet open	Sichuan Cancer Hospital and Research Institute	China
Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma NCT07584733 · ClinicalTrials.gov ↗ · Upper Tract Urothelial Carcinoma	Phase 2	Not yet open	RenJi Hospital	China
SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma NCT07609667 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. NCT07655661 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Ming Liu	China
Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma NCT07678580 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Not yet open	Tang-Du Hospital	China
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study NCT07685704 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer	Phase 2	Not yet open	Zhifeng Zhao, PhD	China
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial NCT07775040 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Not yet open	Sichuan Cancer Hospital and Research Institute	China
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC NCT07776340 · ClinicalTrials.gov ↗ · HPV-unrelated Head and Neck Squamous Cell Carcinoma	Phase 2	Not yet open	Fudan University	China
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma NCT07812467 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma NCT07824856 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases	Phase 2	Not yet open	Sun Yat-sen University	China
Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma NCT07842276 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma (STS), Utidelone, Doxorubicin	Phase 2	Not yet open	Beijing Biostar Pharmaceuticals Co., Ltd	China
Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer NCT07845916 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC NCT06456138 · ClinicalTrials.gov ↗ · KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor	Phase 1/2	Not yet open	Shanghai Chest Hospital	China
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer NCT06871527 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib	Phase 1/2	Not yet open	Sixth Affiliated Hospital, Sun Yat-sen University	China
Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer NCT07025850 · ClinicalTrials.gov ↗ · Colorectal Carcinoma	Phase 1/2	Not yet open	Fudan University	China
Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease NCT07681297 · Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease	Phase 1/2	Not yet open	National University Hospital, Singapore	Singapore
A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors NCT07694765 · ClinicalTrials.gov ↗ · Malignant Tumors	Phase 1/2	Not yet open	LaNova Medicines Limited	Australia
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. NCT07348107 · ClinicalTrials.gov ↗ · Advanced Pancreatic Ductal Adenocarcinoma	Phase 1	Not yet open	Daniel Breadner	Canada
LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer NCT07453875 · ClinicalTrials.gov ↗ · Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT	Phase 1	Not yet open	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance NCT07842887 · ClinicalTrials.gov ↗ · EGFR-TKI-resistant Non-Small Cell Lung Cancer	Phase 1	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC NCT07480382 · ClinicalTrials.gov ↗ · Initially Unresectable Hepatocellular Carcinoma	Not applicable	Not yet open	Hong Wu	China
Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) NCT07389187 · ClinicalTrials.gov ↗ · mCRPC	Early Phase 1	Not yet open	Shanghai Changzheng Hospital	China
Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma NCT06303583 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 1/2	By invitation	Qiu Guoqin	China
A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors NCT07847905 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer	Phase 1/2	By invitation	LaNova Medicines Limited	China
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC NCT07353294 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Lymph Node Metastasis	Phase 1	By invitation	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma NCT03967977 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Active, closed	BeiGene	China, Taiwan
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib NCT04170283 · B-cell Malignancies	Phase 3	Active, closed	BeOne Medicines	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Czechia, Turkey, Japan, South Korea, Taiwan, Australia
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) NCT04379635 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Active, closed	BeiGene	China
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers NCT05152147 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma	Phase 3	Active, closed	Jazz Pharmaceuticals	Ireland, UK, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma NCT05211232 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma NCT06206733 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma	Phase 3	Active, closed	AskGene Pharma, Inc	China
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer NCT06939439 · ClinicalTrials.gov ↗ · Gastric Cancer Stage III	Phase 3	Active, closed	The First Affiliated Hospital with Nanjing Medical University	China
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) NCT04734262 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Active, closed	Fudan University	China
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors NCT04802876 · ClinicalTrials.gov ↗ · MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma	Phase 2	Active, closed	SOLTI Breast Cancer Research Group	Spain
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS) NCT05253118 · ClinicalTrials.gov ↗ · DLBCL	Phase 2	Active, closed	Seoul National University Hospital	South Korea
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer NCT05319574 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 2	Active, closed	Sun Yat-sen University	China
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC NCT05343325 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment	Phase 2	Active, closed	Fifth Affiliated Hospital, Sun Yat-Sen University	China
TIME in Immunotherapy Combined With nCRT for Rectal Cancer NCT05507112 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Active, closed	Peking Union Medical College Hospital	China
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) NCT05520619 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer NCT05531123 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 2	Active, closed	Fudan University	China
First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer NCT05586061 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer	Phase 2	Active, closed	Qilu Hospital of Shandong University	China
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) NCT05724329 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinomas	Phase 2	Active, closed	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) NCT06009861 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma	Phase 2	Active, closed	Peking University Hospital of Stomatology	China
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer NCT06056804 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Active, closed	Beijing Friendship Hospital	China
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer NCT06124378 · ClinicalTrials.gov ↗ · Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors	Phase 2	Active, closed	First Affiliated Hospital of Guangxi Medical University	China
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma NCT06239532 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Active, closed	Qilu Hospital of Shandong University	China
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma NCT06673693 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC	Phase 2	Active, closed	Sun Yat-sen University	China
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma NCT06914687 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis	Phase 2	Active, closed	Fudan University	China
CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer NCT07801352 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer	Phase 2	Active, closed	Shanghai Changzheng Hospital	China
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation NCT04699188 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal	Phase 1/2	Active, closed	Novartis Pharmaceuticals	USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Canada, Japan, South Korea, Taiwan, Singapore, Australia
Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma NCT05464433 · ClinicalTrials.gov ↗ · Extranodal Natural Killer T Cell Lymphoma	Phase 1/2	Active, closed	Sun Yat-sen University	China
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer NCT05609370 · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	Phase 1/2	Active, closed	BeiGene	USA, China, Mexico, Australia
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors NCT05651022 · Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)	Phase 1/2	Active, closed	Indaptus Therapeutics, Inc	USA
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. NCT05661955 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma	Phase 1/2	Active, closed	BeiGene	China
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma NCT07010120 · ClinicalTrials.gov ↗ · HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy	Phase 1/2	Active, closed	West China Hospital	China
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments NCT07468071 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation	Phase 1/2	Active, closed	Novartis Pharmaceuticals	China, France, Spain, Italy, Belgium, Denmark, Canada, Japan, South Korea
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study NCT05167071 · ClinicalTrials.gov ↗ · Solid Tumors, Neuroendocrine Tumors, CRC	Phase 1	Active, closed	Harbour BioMed (Guangzhou) Co. Ltd	China
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors NCT05238883 · Gastric Cancer, Renal Cell Carcinoma, Melanoma	Phase 1	Active, closed	HiFiBiO Therapeutics	USA, Spain
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors NCT05789069 · Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer	Phase 1	Active, closed	HiFiBiO Therapeutics	USA, Spain, Italy
The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer NCT07638878 · ClinicalTrials.gov ↗ · Lung Cancer (Locally Advanced or Metastatic)	Observational	Active, closed	Guangzhou Medical University	China
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer NCT06866548 · ClinicalTrials.gov ↗ · mCRPC	Early Phase 1	Active, closed	Shanghai Changzheng Hospital	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Tislelizumab in the EU trials register (CTIS)

5 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Tislelizumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
Intensified neoadjuvant-aDjuvant management of REsectable esophageal adenocarcInomA: the MultIcentre, phase II, singlE-aRm DREAMER study 2026-526333-25-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Centro Di Riferimento Oncologico Di Aviano	Italy
METIMMOX-3: Using Tumor Mutational Status as Selection Biomarker for First-Line Therapy with Short-Course Oxaliplatin-Based Chemotherapy and Bevacizumab Alternating with Tislelizumab in Metastatic MSS/pMMR Colorectal Cancer 2026-526317-29-00 · CTIS ↗ · Digestive System Diseases	Phase 2	Authorised	Akershus University Hospital	Norway
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer with a High Tumor Burden (HighFive) [without IMPD-Q] 2026-525497-18-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	AIO-Studien gGmbH	Germany
Perioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial 2025-523483-20-00 · Neoplasms	Phase 1	Authorised	UZ Leuven	Belgium
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer 2025-521989-95-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Oncomatryx Biopharma S.L	Spain

Tislelizumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

1 single-substance product containing Tislelizumab on the HPRA medicines list.

Tevimbra 100 mg concentrate for solution for infusionBeiGene Ireland Limited · EU/1/23/1758/001-002

All 1 Irish product →

Supply shortages

No entry for Tislelizumab in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Tislelizumab

286 conditions

Esophageal Squamous Cell Carcinoma11 Gastric Cancer9 Advanced Solid Tumor7 Non-Small Cell Lung Cancer6 Nasopharyngeal Carcinoma6 Gastroesophageal Junction Adenocarcinoma5 Gastric Adenocarcinoma5 Lung Cancer5 Rectal Cancer5 Neoadjuvant Therapy5 HCC - Hepatocellular Carcinoma4 Melanoma4

All 286 conditions

Condition (as registered)	Trials
Esophageal Squamous Cell Carcinoma	11
Gastric Cancer	9
Advanced Solid Tumor	7
Non-Small Cell Lung Cancer	6
Nasopharyngeal Carcinoma	6
Gastroesophageal Junction Adenocarcinoma	5
Gastric Adenocarcinoma	5
Lung Cancer	5
Rectal Cancer	5
Neoadjuvant Therapy	5
HCC - Hepatocellular Carcinoma	4
Melanoma	4
Non Small Cell Lung Cancer	4
Tislelizumab	4
PD-1 Inhibitor	4
Colorectal Cancer	4
Intrahepatic Cholangiocarcinoma	4
Gastroesophageal Adenocarcinoma	3
Renal Cell Carcinoma	3
Locally Advanced Rectal Cancer	3
Hepatocellular Carcinoma (HCC)	3
NSCLC (Non-small Cell Lung Cancer)	3
Esophageal Squamous Cell Carcinoma (ESCC)	3
Esophageal Adenocarcinoma	2
Carcinoma, Non-Small-Cell Lung	2
Solid Tumor, Adult	2
Solid Tumor	2
Chemotherapy	2
Classical Hodgkin Lymphoma	2
Advanced Solid Tumour	2
ESCC	2
Oral Squamous Cell Carcinoma	2
Advanced Solid Tumor Cancer	2
Urothelial Carcinoma	2
NSCLC (Advanced Non-small Cell Lung Cancer)	2
Extensive-stage Small-cell Lung Cancer	2
Bladder Cancer	2
Metastatic Colorectal Cancer	2
HNSCC	2
Immunotherapy	2
Triple-negative Breast Cancer	2
Advanced Hepatocellular Carcinoma	2
Head and Neck Squamous Cell Carcinoma	2
HER2-positive Gastric Cancer	2
NSCLC	2
Colonic Neoplasms	2
Immune Checkpoint Inhibitors	2
Locally Advanced Esophageal Squamous Cell Carcinoma	2
Gastric Carcinoma	2
Hepatocellular Carcinoma	2
Neoadjuvant Immunotherapy	2
LDRT	2
mCRPC	2
Upper Tract Urothelial Carcinoma	2
Head and Neck Squamous Cell Carcinoma (HNSCC)	2
Cholangiocarcinoma	2
Gastric Neoplasms	1
B-cell Malignancies	1
NSCLC Stage IV	1
Metastatic Gastric Adenocarcinoma	1
KRAS G12C Mutant Solid Tumors	1
Carcinoma, Colorectal	1
Cancer of Lung	1
CRC (Colorectal Cancer)	1
Pancreatic Adenocarcinoma	1
Advanced Unresectable Gastric Adenocarcinoma	1
Advanced Gastroesophageal Adenocarcinoma	1
Advanced Solid Tumors	1
Sarcoma	1
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	1
Pancreatic Ductal Adenocarcinoma	1
Pancreatic Adenocarcinoma Metastatic	1
Metastatic Hepatocellular Carcinoma	1
Local Advanced Hepatocellular Carcinoma	1
Alpha-fetoprotein (AFP)-Producing Gastric Cancer	1
Extragonadal Yolk Sac Tumors	1
Lung Cancer (NSCLC)	1
Esophageal Neoplasms	1
Initially Unresectable Hepatocellular Carcinoma	1
Advanced and Metastatic NSCLC	1
Esophageal Squamous Cell Carcinoma Stage II	1
Esophageal Squamous Cell Carcinoma Stage III	1
Oligodendroglioma	1
Gastric Cancer Stage III	1
Advanced or Recurrent Solid Tumors	1
Unresectable Stage III Non-small Cell Lung Cancer	1
Chemoembolization, Therapeutic	1
Child	1
Adolescent	1
Young Adult	1
Neoadjuvant Chemoimmunotherapy	1
Adjuvant Therapy	1
B-NHL	1
CART Therapy	1
Advanced Non-small Cell Lung Cancer	1
Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma	1
Non Squamous Non-small Cell Lung Cancer	1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)	1
Recurrent Glioblastoma	1
Surufatinib	1
Concurrent Chemoradiotherapy	1
Consolidation Therapy	1
Colorectal Carcinoma	1
Lung Cancer (Locally Advanced or Metastatic)	1
Becotatug Vedotin	1
Metastatic Breast Cancer	1
Extranodal Natural Killer T Cell Lymphoma	1
MCRC	1
Soft Tissue Sarcoma (STS)	1
Utidelone	1
Doxorubicin	1
Anti Angiogenesis	1
Lung Carcinoma	1
Astrocytoma of Brain	1
Locally Advanced Colorectal Cancer	1
Angioimmunoblastic T-Cell Lymphoma Recurrent	1
Angioimmunoblastic T-Cell Lymphoma Refractory	1
HPV-unrelated Head and Neck Squamous Cell Carcinoma	1
HPV-positive Oropharyngeal Squamous Cell Carcinoma	1
Lysogenic HSV Virus	1
Extensive-stage Small Cell Lung Cancer	1
Recurrent Hepatocellular Carcinoma	1
Lung Cancer, Non-Small Cell	1
Gastric (Stomach) Cancer	1
Fruquintinib	1
Oral Squamous Cell Carcinoma (OSCC)	1
Oropharyngeal Squamous Cell Carcinoma (OPSCC)	1
Microsatellite Instability High	1
Esophageal Cancer Stage III	1
Head &Amp; Neck Squamous Cell Carcinoma	1
Neoadjuvant Treatment	1
Rectal Neoplasms	1
Rectal Cancer, Adenocarcinoma	1
Muscle Invasive Bladder Cancer (MIBC)	1
Gastric	1
Colorectal Adenocarcinoma	1
Small Cell Lung Cancer Extensive Stage	1
Renal Pelvic Carcinoma	1
Kidney-sparing	1
Relapsed/Refractory Follicular Lymphoma	1
Non-small Cell Lung Cancer	1
Bladder Urothelial Carcinoma	1
Lymph Node Metastasis	1
Peripheral T Cell Lymphoma	1
Perioperative Immunotherapy	1
Limited Stage Lung Small Cell Carcinoma	1
Resectable Small Cell Lung Cancer	1
Intrahepatic Cholangiocellular Carcinoma	1
Urinary Bladder Neoplasms	1
BCG Vaccine	1
Immunotherapy, Active	1
Multicenter Study	1
New Diagnosed Angioimmunoblastic T-Cell Lymphoma	1
Immunotherapy Esophagus Cancer	1
Cervical Cancer	1
Patients With Locally Advanced or Metastatic NSCLC Who Have Failed First-line Immunotherapy	1
Bone Metastases	1
Glioblastoma	1
Colon Adenocarcinoma	1
SCLC, Limited Stage	1
Microsatellite Stable Colorectal Carcinoma	1
Adjuvant Immunotherapy	1
Oropharyngeal Squamous Cell Carcinoma	1
Liver Cancer	1
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer	1
Advanced Solid Tumors Harboring the KRAS G12C Mutation	1
Intrahepatic Cholangiocarcinoma (Icc)	1
Non-squamous Non-small Cell Lung Cancer	1
Advanced Non-squamous Non-small-cell Lung Cancer	1
Metastatic Non-squamous Non Small Cell Lung Cancer	1
KRAS Mutation-Related Tumors	1
Advanced Lung Cancer	1
Refractory Tumor	1
Head and Neck Squamous Cell Carcinomas	1
Liver Metastasis	1
Rectal Cancer Stage II	1
Rectal Cancer Stage III	1
Advanced Thyroid Carcinoma	1
Radioiodine-refractory Differentiated Thyroid Cancer	1
Poorly Differentiated Thyroid Carcinoma	1
Nasopharyngeal Carcinoma (NPC)	1
Small Cell Lung Cancer	1
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma	1
Peritoneal Metastasis	1
Soft Tissue Sarcomas	1
Angiosarcoma	1
Fibrosarcoma	1
Leiomyosarcoma	1
Locally Advanced Rectal Carcinoma	1
MSI-H/dMMR Solid Tumors	1
Non-mucosal Melanoma	1
Laryngeal Cancer	1
Hypopharynx Cancer	1
Laryngeal Neoplasms	1
Nab-paclitaxel	1
Double Blind	1
HCC	1
Locally Advanced or Metastatic NSCLC	1
Locally Advanced Unresectable Esophageal Cancer	1
Diabetes	1
Gastric Cancer Stage	1
Squamous Cell Carcinoma of External Auditory Canal	1
Locally Advanced Tumor	1
Local Recurrence	1
Peritoneal Metastasis of Gastric and Colorectal Cancer	1
Head & Neck Cancer	1
Locally Advanced or Metastatic Solid Tumors	1
LA HNSCC	1
Gastric or Esophagogastric Junction Adenocarcinoma	1
NSCLC Associated With Leptomeningeal Metastases	1
Hilar Cholangiocarcinoma	1
Bile Duct Cancer	1
Muscle Invasive Bladder Cancer	1
NMIBC	1
Lenvatinib	1
Hepatic Arterial Infusion Chemotherapy	1
Adenocarcinoma	1
Anti-PD1/PDL1 Antibody	1
Bevacizumab	1
Squamous Non-Small Cell Lung Cancer sqNSCLC	1
Extensive-stage Small Cell Lung Cancer (ES-SCLC)	1
EGFR-TKI-resistant Non-Small Cell Lung Cancer	1
SCLC, Extensive Stage	1
Hepato Cellular Carcinoma (HCC)	1
Immunotherapy Gastrict Cancer	1
Gastric Cancer, Gastroesophageal Junction Cancer	1
Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations	1
Resectable NSCLC	1
Tongue Squamous Cell Carcinoma	1
Gastric Cancer Stage IV	1
Locally Recurrent Colorectal Cancer	1
Neoplasm Metastasis	1
Lung Metastases	1
Liver Metastases	1
Metastatic Colorectal Cancer，NED	1
Stomach Neoplasms	1
Linitis Plastica of Stomach	1
Upper Urinary Tract Urothelial Carcinoma	1
Kidney Preservation	1
HER-2 ADC	1
PD-1antibody	1
Solid Tumors	1
Neuroendocrine Tumors	1
CRC	1
Bladder (Urothelial, Transitional Cell) Cancer	1
Extranodal NK/T-cell Lymphoma	1
NK/T-cell Lymphoma	1
Relapsed or Refractory NK/T-Cell Lymphoma	1
Gastroesophageal-junction Cancer	1
Locally Advanced Prostate Cancer	1
Oligometastatic Prostate Cancer	1
Biliary Tract Carcinoma	1
Non-small Cell Lung Cancer Metastatic	1
Richter Transformation	1
Locally Advanced Rectal Cancer (LARC)	1
Esophagogastric Junction Adenocarcinoma	1
Resectable Esophagogastric Adenocarcinoma	1
Cancer	1
Colo-rectal Cancer	1
Pancreas Cancer	1
Advanced Non-Small Cell Lung Cancer	1
Extensive-Stage Small Cell Lung Cancer	1
MSI-H Colorectal Cancer	1
Anal Carcinoma	1
Mesothelioma	1
Hodgkin Lymphoma	1
Stage III NSCLC	1
Pseudomyxoma Peritonei	1
Large B-cell Lymphoma	1
Advanced Pancreatic Ductal Adenocarcinoma	1
Advanced Esophageal Squamous Cell Carcinoma	1
Metastatic Esophageal Squamous Cell Carcinoma	1
DLBCL	1
Lymphoma	1
Colorectal Cancer (Diagnosis)	1
Colorectal Cancer Metastatic	1
Colorectal Cancer (CRC)	1
Biliary Tract Cancer (BTC)	1
Total Neoadjuvant Treatment	1
Pathological Complete Response	1
Triple-Negative Breast Cancer (TNBC)	1
CNS Disease	1
Breast Cancer	1
RAS Mutation	1
Metastatic Solid Tumor	1
Malignant Tumors	1

By country register

Register	Trials	Recruiting
Clinical trials in China	217	136
Clinical trials in USA	17	11
Clinical trials in Spain	13	5
Clinical trials in Germany	11	6
Clinical trials in Australia	11	6
Clinical trials in Italy	10	4
Clinical trials in Japan	10	6
Clinical trials in South Korea	9	4
Clinical trials in Taiwan	8	3
Clinical trials in France	7	3
Clinical trials in Canada	7	3
Clinical trials in UK	4	2
Clinical trials in Brazil	4	3
Clinical trials in Netherlands	3	0
Clinical trials in Belgium	3	0
Clinical trials in Poland	3	1
Clinical trials in Turkey	3	1
Clinical trials in Mexico	3	1
Clinical trials in Singapore	3	0
Clinical trials in Austria	3	3
Clinical trials in Denmark	3	1
Clinical trials in Israel	3	3
Clinical trials in Czechia	2	1
Clinical trials in Egypt	2	2
Clinical trials in Ireland	1	0
Clinical trials in India	1	0
Clinical trials in Portugal	1	0
Clinical trials in Sweden	1	0
Clinical trials in Norway	1	1
EU register (CTIS)	5	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Tislelizumab trials

How many clinical trials are testing Tislelizumab?

251 current trials in our China, USA, Spain, Germany, Australia, Italy, Japan, South Korea, Taiwan, France, Canada, UK, Brazil, Netherlands, Belgium, Poland, Turkey, Mexico, Singapore, Austria, Denmark, Israel, Czechia, Egypt, Ireland, India, Portugal, Sweden and Norway registers name Tislelizumab (also registered as BGB-A317) as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.

Are Tislelizumab trials recruiting patients?

Yes. 159 of the 251 trials are recruiting: 136 with sites in China, 11 with sites in USA, 5 with sites in Spain, 6 with sites in Germany, 6 with sites in Australia, 4 with sites in Italy, 6 with sites in Japan, 4 with sites in South Korea, 3 with sites in Taiwan, 3 with sites in France, 3 with sites in Canada, 2 with sites in UK, 3 with sites in Brazil, 1 with sites in Poland, 1 with sites in Turkey, 1 with sites in Mexico, 3 with sites in Austria, 1 with sites in Denmark, 3 with sites in Israel, 1 with sites in Czechia, 2 with sites in Egypt and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Tislelizumab clinical trials?

Fudan University (18), Sun Yat-sen University (15), BeOne Medicines (11) and Fujian Cancer Hospital (6), among 127 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Tislelizumab clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Tislelizumab licensed in Ireland?

Yes. The HPRA medicines list includes 1 single-substance product containing Tislelizumab, for example Tevimbra 100 mg concentrate for solution for infusion (BeiGene Ireland Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Tislelizumab shortage?

Not in the lists we track: Tislelizumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tislelizumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tislelizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tislelizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Tislelizumab clinical trials

Where Tislelizumab is approved

How Tislelizumab works

NICE appraisals of Tislelizumab

Patient leaflets for Tislelizumab

Trials by status

Trials by phase

Clinical trials of Tislelizumab

Tislelizumab in the EU trials register (CTIS)

Tislelizumab across our data

Licensed in Ireland (HPRA)

Supply shortages

Conditions studied with Tislelizumab

Sponsors

By country register

Related compounds

In the same trials as Tislelizumab

Other compounds in Esophageal Squamous Cell Carcinoma trials

Questions about Tislelizumab trials

How this page is built